Travere Therapeutics Announces Interim Analysis from the

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control...

Related Keywords

Japan ,United States ,Bangkok ,Krung Thep Mahanakhon ,Thailand ,Naomi Eichenbaum ,Nivi Nehra ,Brad Rovin ,Exchange Commission ,Travere Therapeutics Inc ,Nasdaq ,World Congress ,Corporate Communications ,Division For Nephrology ,Ohio State University Center ,Clinical Research Management ,European Union ,Company Annual Report On Form ,Medical Director ,About Iga ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Travere Therapeutics ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Tvtx ,Nc ,Iga Nephropathy ,Lancet ,Proteinuria ,Protect Study ,Cn ,Rare Kidney Disease ,Nephrology ,